Danaher Corporation (NYSE:DHR – Get Free Report) SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Danaher Stock Up 1.8%
NYSE:DHR traded up $3.81 during mid-day trading on Wednesday, hitting $219.60. 4,323,858 shares of the company’s stock traded hands, compared to its average volume of 4,184,731. The company has a fifty day moving average of $204.36 and a 200 day moving average of $200.64. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The company has a market capitalization of $155.11 billion, a P/E ratio of 45.28, a P/E/G ratio of 3.28 and a beta of 0.81.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same quarter last year, the company earned $1.71 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.
Danaher Dividend Announcement
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on DHR shares. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. TD Cowen boosted their price target on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Rothschild & Co Redburn reaffirmed a “neutral” rating and set a $220.00 target price (down previously from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Finally, Wells Fargo & Company restated a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.
View Our Latest Stock Report on DHR
Institutional Investors Weigh In On Danaher
A number of institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new stake in shares of Danaher in the second quarter valued at about $1,979,503,000. Nuveen LLC purchased a new position in Danaher in the 1st quarter valued at about $833,941,000. Viking Global Investors LP boosted its holdings in Danaher by 543.9% in the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock worth $574,351,000 after buying an additional 2,455,994 shares during the last quarter. Generation Investment Management LLP increased its stake in Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock worth $980,914,000 after buying an additional 1,787,522 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Rare Earth Stocks: The Truce That Isn’t a Truce
- What is Forex and How Does it Work?
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- Dividend Payout Ratio Calculator
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
